Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is pecoma (perivascular epithelioid cell tumor)?
PEComa stands for 'perivascular epithelioid cell tumor' — a family of rare tumors made of distinctive cells that wrap around small blood vessels and share features of both muscle and pigment cells. PEComas can arise almost anywhere in the body: the uterus, the gastrointestinal tract, the kidney, the lungs, and soft tissues. Most PEComas are benign or of uncertain (borderline) potential and are cured simply by removing them. A minority are malignant and can spread. The most important biological insight is that PEComas are usually driven by loss of the TSC1 or TSC2 genes, which switches on a growth pathway called mTOR — the same pathway involved in the genetic condition tuberous sclerosis, with which some PEComas are associated. This discovery led to a targeted treatment: mTOR-inhibitor drugs that switch the pathway back off. In 2021 the FDA approved nab-sirolimus (Fyarro) specifically for advanced malignant PEComa.
The main types
Doctors group pecoma (perivascular epithelioid cell tumor) by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Benign PEComa | The most common category — a tumor with no worrisome features that is cured by complete surgical removal and does not spread. |
| PEComa of uncertain malignant potential | A borderline tumor with one or two concerning features. It is removed completely and watched, since behavior can't be predicted with certainty. |
| Malignant PEComa | An uncommon cancerous form with multiple worrisome features (large size, high cell division, invasion). It can spread and is now treated with the mTOR-inhibitor drug nab-sirolimus. |
Staging, in plain terms
PEComas do not have their own staging system. When malignant, they are staged like soft-tissue sarcomas — based on tumor size and depth (T), lymph-node spread (N, uncommon), and distant spread (M) — and their grade. More practically, pathologists classify each PEComa as benign, uncertain, or malignant using features such as size, cell-division rate, invasion into surrounding tissue, and dead (necrotic) areas. This benign-to-malignant classification, more than a numeric stage, drives treatment decisions.
| Soft-tissue sarcoma TNM + malignancy criteria | What it generally means |
|---|---|
| Benign / localized | A tumor with no or minimal worrisome features, confined to where it started. Cured by complete surgical removal. |
| Uncertain or high-risk localized | A borderline or malignant tumor still confined to one area. Treated with complete surgery, sometimes with radiation, and close follow-up. |
| Metastatic | A malignant PEComa that has spread to distant organs. Treated with the mTOR-inhibitor drug nab-sirolimus, with surgery or radiation for selected problem areas. |
The standard of care
PEComa (Perivascular Epithelioid Cell Tumor) is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery (the main treatment for localized disease)
Completely removing the tumor with clear margins cures benign and borderline PEComas and is the first treatment for malignant tumors that can be removed.
mTOR-inhibitor therapy (nab-sirolimus)
Because PEComas are driven by the mTOR pathway, the mTOR-inhibitor drug nab-sirolimus (Fyarro) is FDA-approved for advanced malignant PEComa and can shrink tumors and control disease for extended periods.
Radiation therapy
Radiation is used selectively — after surgery for close or positive margins, for tumors that can't be removed, or to treat painful or growing spots — since experience with radiation in this rare tumor is limited but it can help local control.
Expert sarcoma-center care and follow-up
Because PEComas are rare and span a wide range of behavior, an experienced sarcoma team with molecular testing plans treatment and monitors for recurrence or spread over time.
How radiation treatment works
Radiation damages the DNA inside cancer cells so they can no longer divide. For PEComa, surgery is the main treatment for tumors that can be removed, and the targeted drug nab-sirolimus is the key treatment for advanced disease — but radiation has a useful supporting role. It is used after surgery when margins are close or positive, for tumors that can't be safely removed, and to treat painful or growing spots, including a small number of metastases with focused stereotactic radiation (SBRT). Shaped external-beam radiation concentrates the dose on the target while sparing surrounding organs. Because PEComas are rare, radiation is tailored case by case by an expert team. Radiation is painless during delivery, given over one or more sessions depending on the technique, and external-beam treatment leaves no radioactivity in the body.
The main ways radiation is delivered for pecoma (perivascular epithelioid cell tumor):
External-beam radiation (IMRT)
Shaped beams treat the tumor or tumor bed while sparing surrounding organs, useful after surgery with close margins or for tumors that can't be removed.
Stereotactic body radiation (SBRT)
Focused high-dose radiation can precisely treat a small number of metastatic spots, for example in the lung, to control limited spread.
Brachytherapy (selected uterine PEComa)
For some PEComas of the uterus, radiation sources placed close to the area can deliver a concentrated dose while sparing nearby tissue.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
FDA approval of nab-sirolimus for malignant PEComa: Based on the AMPECT trial, nab-sirolimus (Fyarro) — a nanoparticle albumin-bound mTOR inhibitor — was FDA-approved for advanced malignant PEComa, with about 39% of patients responding and some responses lasting a long time, establishing the first approved drug for this cancer.[1]
AMPECT trial and FDA approval (CancerNetwork / OncLive reporting)
TSC1/TSC2 loss drives the mTOR pathway: Research showed that most PEComas lose the TSC1 or TSC2 genes, switching on mTOR signaling, which explains the tumor's behavior and why mTOR-inhibitor drugs work — and links some PEComas to tuberous sclerosis.[2]
Modern Pathology and Journal of Clinical Oncology biomarker analyses
Combination strategies under study: For PEComas that progress on mTOR inhibitors, researchers are studying combinations adding anti-angiogenic drugs or immunotherapy, reflecting ongoing efforts to extend control of advanced disease.[3]
Frontiers in Oncology and sarcoma trial reports (2025)
Common questions
Is PEComa always cancer? No. PEComa is a family of tumors that ranges from benign to malignant. Most are benign or borderline and are cured simply by removing them. Only a minority are truly malignant and able to spread. Pathologists classify each tumor using features like size and cell-division rate to predict how it will behave.
What makes nab-sirolimus work for PEComa? Most PEComas are driven by an overactive growth pathway called mTOR, usually because of loss of the TSC1 or TSC2 genes. Nab-sirolimus blocks mTOR, switching the growth signal back off. Because the drug matches the tumor's biology, it can shrink advanced malignant PEComas — which is why the FDA approved it specifically for this cancer.
Where does radiation fit in? Surgery and, for advanced disease, nab-sirolimus are the mainstays. Radiation plays a supporting role — used after surgery when margins are close or positive, for tumors that can't be removed, or to treat painful or growing spots, including a few metastases with focused SBRT. Your sarcoma team will decide if radiation is helpful in your case.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- AMPECT trial and FDA approval (CancerNetwork / OncLive reporting) (no indexed identifier — see your care team) ↩
- Modern Pathology and Journal of Clinical Oncology biomarker analyses (no indexed identifier — see your care team) ↩
- Frontiers in Oncology and sarcoma trial reports (2025) (no indexed identifier — see your care team) ↩